| High Grade Endometrial Carcinoma studied in …STUDIED_INderived10 of 63show all (up to 200) |
|---|
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 63 trials mapped (20 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | Endometrial Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | High Grade Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792552Phase 1 · recruiting A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 63 trials mapped (20 active) | — | — | Endometrial Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 63 trials mapped (20 active) | — | — | Endometrial Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 63 trials mapped (20 active) | — | — | Endometrial Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |